Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Reaching for a diet soda or artificially sweetened snack to lose weight or to enjoy a few more treats? A growing number of scientists believe that’s not a good idea.

(RTTNews) - Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in ...

The long quest for powerful non-opioid drugs that treat pain without risk of addiction is nearing a milestone, in the form of a pill that could soon win approval from the Food and Drug Administration.

UAE -- The U.S. Food and Drug Administration (FDA) approved lately Tirzepatide ... to-severe obstructive sleep apnea and obesity. It is also approved in combination with a reduced-calorie diet and ...

WEDNESDAY, Jan. 8, 2025 (HealthDay News) -- Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. However, a ...

They investigated 12 medications — three that the US Food and Drug Administration (FDA) has approved for weight loss and nine it hasn’t. The drugs mimic GLP-1, a hormone the body naturally ...

The key lies in adopting proven strategies that focus on sustainable lifestyle changes rather than quick fixes. A well-balanced diet combined with regular exercise and stress management are essential ...

The drug application seeks accelerated FDA approval, with a priority review potentially leading to a U.S. commercial launch next year. The ongoing phase 3 ACTION trial evaluates dordaviprone's impact ...

while Hikma has already rolled out its own copycat following an FDA approval that came through shortly after Christmas. Complicating the issue for Novo, generic drug makers and compounders ...